Platelet adp receptor inhibitors

Abstract

Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt thereof.

1 - 20 . (canceled) 
     
     
         21 . A compound selected from the group consisting of: 
       
         
           
           
               
               
           
         
       
     
     
         22 . A pharmaceutical composition comprising a therapeutically effective amount of a compound according to  claim 21 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
     
     
         23 . A pharmaceutical composition of  claim 22 , wherein said therapeutically effective amount is an amount effective to inhibit platelet aggregation in the mammal. 
     
     
         24 . A method for preventing or treating thrombosis in a mammal comprising the step of administering to a mammal a therapeutically effective amount of a compound of  claim 21  or a pharmaceutically acceptable salt thereof. 
     
     
         25 . A method of  claim 24 , wherein said mammal is a human. 
     
     
         26 . A method of  claim 24 , wherein said cardiovascular disease is at least one selected from the group consisting of acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary artery bypass graft) surgery, vascular graft surgery, stent placements and insertion of endovascular devices and protheses.